BC Week In Review | Apr 27, 2018
Company News

Tonghua gets rights to two insulin products from Adocia

Adocia S.A. (Euronext:ADOC) granted Tonghua Dongbao Pharmaceutical Co. Ltd. (Shanghai:600867) exclusive rights to develop and commercialize BioChaperone Lispro (BioChaperone Ultra fast-acting insulin analog) and BioChaperone insulin combo in China and other undisclosed countries. Adocia will...
BC Week In Review | Jul 28, 2017
Clinical News

Adocia begins head-to-head trial of BioChaperone Lispro vs. Fiasp and Novolog

In early June, Adocia S.A. (Euronext:ADOC) began a 3-way crossover Phase II trial to compare single subcutaneous doses of 0.15 U/kg BioChaperone Lispro vs. 0.15 U/kg Fiasp ( faster-acting insulin aspart , NN1218) or 0.15 U/kg Novolog...
BC Week In Review | Feb 3, 2017
Company News

Adocia, Lilly deal

Eli Lilly terminated a 2014 deal and returned rights to Adocia's BioChaperone Lispro to treat Type I and Type II diabetes. Lilly had paid $50 million up front for exclusive, worldwide rights to the ultra-fast-acting...
BC Extra | Jan 27, 2017
Company News

Lilly returns diabetes candidate to Adocia

Adocia S.A. (Euronext:ADOC) sank EUR 12.67 (31%) to EUR 27.60 after it said Eli Lilly and Co. (NYSE:LLY) terminated a 2014 deal and returned rights to Adocia's BioChaperone Lispro to treat Type I and Type...
BC Extra | Aug 26, 2016
Clinical News

Adocia halting diabetic foot ulcer programs after Phase III miss

Adocia S.A. (Euronext:ADOC) said its BioChaperone PDGF-BB spray missed the primary endpoint in an Indian Phase III study to treat diabetic foot ulcers. The candidate did not significantly improve complete wound closure after 20 weeks...
BC Week In Review | Apr 11, 2016
Clinical News

BioChaperone Lispro: Phase Ib data

Top-line data from a double-blind, crossover, German Phase Ib trial in 36 Type I diabetics showed that subcutaneous BioChaperone Lispro U100 given at mealtime significantly reduced blood glucose excursion vs. Humalog insulin lispro over the...
BC Week In Review | Feb 8, 2016
Clinical News

BioChaperone Lispro: Phase Ib started

Adocia and Eli Lilly began a double-blind, 3-period crossover, German Phase Ib trial to compare 3 single doses of 0.1, 0.2 and 0.4 U/kg BioChaperone Lispro every 1-14 days vs. 1 single dose of 0.2...
BC Week In Review | Jan 18, 2016
Clinical News

BioChaperone Lispro: Phase I data

A 4-way crossover, double-blind Phase I trial in 26 healthy volunteers under euglycemic clamp showed that 0.2 U/kg doses of subcutaneous BioChaperone Lispro U200 retained the ultra-rapid profile of 0.2 U/kg doses of BioChaperone Lispro...
BC Week In Review | Oct 19, 2015
Clinical News

BioChaperone Lispro: Phase Ib started

Adocia and Eli Lilly began a double-blind, crossover, German Phase Ib trial to compare continuous subcutaneous BioChaperone Lispro delivered via an insulin pump vs. Humalog insulin lispro for 14 days prior to an individualized standard...
BC Week In Review | Oct 12, 2015
Clinical News

BioChaperone Lispro: Phase Ib started

Adocia and Eli Lilly began a double-blind, crossover, German Phase Ib trial to compare subcutaneous BioChaperone Lispro on days 1, 2, 13 and 14 before a standardized meal vs. Humalog insulin lispro from Lilly in...
Items per page:
1 - 10 of 22